Brian Adams sold $744k of KYMR
Chief Legal Officer at Kymera Therapeutics, Inc.. 6,371 shares at an average of $116.83, traded Sep 4, 2026, filed Sep 4, 2026.
Score components
- +15RoleOfficer
- +21Trade size$744k at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-383874, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | SOpen-market sale Common Stock | -1,209 | $115.55 | $140k | 55,416 | 38 d ago |
| Sep 4, 2026 | SOpen-market sale Common Stock | -3,025 | $116.81 | $353k | 52,391 | 38 d ago |
| Sep 4, 2026 | SOpen-market sale Common Stock | -2,137 | $117.57 | $251k | 50,254 | 38 d ago |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 50Moderate | KYMRbuy Kymera Therapeutics, Inc. | Baker Bros. Advisors LP director, owner | $172M 2,005,813 shares | +376% | |
| 17Weak | Kymera Therapeutics, Inc. | Jeffrey W. Albers director | $449k 5,000 shares | -100% | |
| 14Weak | Kymera Therapeutics, Inc. | Jeffrey W. Albers director | $296k 5,000 shares | -100% | |
| 30Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $4.0M 79,220 shares | -26% | |
| 23Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $1.5M 30,000 shares | -4% | |
| 55Moderate | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $14M 317,167 shares | +12% | |
| 62Notable | Kymera Therapeutics, Inc. | Baker Bros. Advisors LP director | $29M 655,500 shares | +137% | |
| 27Weak | Kymera Therapeutics, Inc. | Elena Ridloff director | $225k 4,500 shares | -100% | |
| 29Weak | Kymera Therapeutics, Inc. | Jeffrey W. Albers director | $311k 6,349 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.